Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
News|Podcasts|October 30, 2026
Evidence with Purpose, Making Real-World Research Better Not Just Faster
Author(s)PurpleLab
What you’ll learn:
- Identify how definitional drift impacts market sizing and target lists: Discover why identical claims datasets can yield multi-million patient swings in cohort size, and how unexamined code choices misallocate commercial spend and field resources.
- Evaluate data quality and denominator stability before building forecasts: Learn what to ask data partners, why unprojected claims provide a more reliable baseline than statistical projections, and how longitudinal eligibility data removes ambiguity.
- Apply a 4-part framework to generate verifiable, purpose-driven evidence: Master the core requirements needed to produce real-world evidence that withstands payer and regulatory scrutiny, while leveraging initiatives like PurpleLab CARES to support community research.
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Trending on PharmExec
1
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
2
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
3
FDA Approves Ilumya for Adults With Active Psoriatic Arthritis
4
Closing the Pediatric Evidence Gap
5